• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of postmedjPostgraduate Medical JournalCurrent TOCInstructions for authors
Postgrad Med J. Jan 1996; 72(843): 45–50.
PMCID: PMC2398308

A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction.

Abstract

In a randomised, double-blind placebo-controlled trial, the effects of the administration of oral L-carnitine (2 g/day) for 28 days were compared in the management of 51 (carnitine group) and 50 (placebo group) patients with suspected acute myocardial infarction. At study entry, the extent of cardiac disease, cardiac enzymes and lipid peroxides were comparable between the groups, although both groups showed an increase in cardiac enzymes and lipid peroxides. At the end of the 28-day treatment period, the mean infarct size assessed by cardiac enzymes showed a significant reduction in the carnitine group compared to placebo. Electrocardiographic assessment of infarct size revealed that the QRS-score was significantly less in the carnitine group compared to placebo (7.4 +/- 1.2 vs 10.7 +/- 2.0), while serum aspartate transaminase and lipid peroxides showed significant reduction in the carnitine group. Lactate dehydrogenase measured on the sixth or seventh day following infarction showed a smaller rise in the carnitine group compared to placebo. Angina pectoris (17.6 vs 36.0%), New York Heart Association class III and IV heart failure plus left ventricular enlargement (23.4 vs 36.0%) and total arrhythmias (13.7 vs 28.0%) were significantly less in the carnitine group compared to placebo. Total cardiac events including cardiac deaths and nonfatal infarction were 15.6% in the carnitine group vs 26.0% in the placebo group. It is possible that L-carnitine supplementation in patients with suspected acute myocardial infarction may be protective against cardiac necrosis and complications during the first 28 days.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Opie LH. Role of carnitine in fatty acid metabolism of normal and ischemic myocardium. Am Heart J. 1979 Mar;97(3):375–388. [PubMed]
  • Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet. 1982 Jun 19;1(8286):1419–1420. [PubMed]
  • Ende N, Rameshwar P, Ende M. Fetal cord blood's potential for bone marrow transplantation. Life Sci. 1989;44(25):1987–1990. [PubMed]
  • Pierpont ME, Judd D, Goldenberg IF, Ring WS, Olivari MT, Pierpont GL. Myocardial carnitine in end-stage congestive heart failure. Am J Cardiol. 1989 Jul 1;64(1):56–60. [PubMed]
  • Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol. 1990 Mar 15;65(11):755–760. [PubMed]
  • Suzuki Y, Masumura Y, Kobayashi A, Yamazaki N, Harada Y, Osawa M. Myocardial carnitine deficiency in chronic heart failure. Lancet. 1982 Jan 9;1(8263):116–116. [PubMed]
  • Shug AL, Thomsen JH, Folts JD, Bittar N, Klein MI, Koke JR, Huth PJ. Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys. 1978 Apr 15;187(1):25–33. [PubMed]
  • Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest. 1989 Mar;83(3):927–936. [PMC free article] [PubMed]
  • Goa KL, Brogden RN. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs. 1987 Jul;34(1):1–24. [PubMed]
  • Cacciatore L, Cerio R, Ciarimboli M, Cocozza M, Coto V, D'Alessandro A, D'Alessandro L, Grattarola G, Imparato L, Lingetti M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17(4):225–235. [PubMed]
  • Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18(8):355–365. [PubMed]
  • Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–421. [PubMed]
  • Cederblad G, Lindstedt S. A method for the determination of carnitine in the picomole range. Clin Chim Acta. 1972 Mar;37:235–243. [PubMed]
  • Bernier M, Hearse DJ, Manning AS. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart. Circ Res. 1986 Mar;58(3):331–340. [PubMed]
  • Singh RB, Niaz MA, Sharma JP, Kumar R, Bishnoi I, Begom R. Plasma levels of antioxidant vitamins and oxidative stress in patients with acute myocardial infarction. Acta Cardiol. 1994;49(5):441–452. [PubMed]
  • Liedtke AJ, Nellis SH. Effects of carnitine in ischemic and fatty acid supplemented swine hearts. J Clin Invest. 1979 Aug;64(2):440–447. [PMC free article] [PubMed]
  • Siliprandi N, Di Lisa F, Toninello A. Biochemical derangements in ischemic myocardium: the role of carnitine. G Ital Cardiol. 1984 Oct;14(10):804–808. [PubMed]
  • Cherchi A, Lai C, Onnis E, Orani E, Pirisi R, Pisano MR, Soro A, Corsi M. Propionyl carnitine in stable effort angina. Cardiovasc Drugs Ther. 1990 Apr;4(2):481–486. [PubMed]
  • Cherchi A, Lai C, Angelino F, Trucco G, Caponnetto S, Mereto PE, Rosolen G, Manzoli U, Schiavoni G, Reale A, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985 Oct;23(10):569–572. [PubMed]
  • Palazzuoli V, Mondillo S, Faglia S, D'Aprile N, Camporeale A, Gennari C. Valutazione dell'attività antiaritmica della L-carnitina e del propafenone nella cardiopatia ischemica. Clin Ter. 1993 Feb;142(2):155–159. [PubMed]
  • Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995 Aug;26(2):380–387. [PubMed]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...